Literature DB >> 27190178

Universal Mass Vaccination Against Rotavirus: Indirect Effects on Rotavirus Infections in Neonates and Unvaccinated Young Infants Not Eligible for Vaccination.

Martina Prelog1, Peter Gorth1, Ines Zwazl2, Michael Kleines3, Andrea Streng1, Manuela Zlamy4, Peter Heinz-Erian4, Ursula Wiedermann2.   

Abstract

BACKGROUND: Rotavirus (RV)-associated infections account for high numbers of hospitalizations in neonates and young infants. Universal mass vaccination (UMV) has been shown to prevent the burden of disease in vaccinated children.
METHODS: The present study investigated the long-term effects of UMV on RV-associated hospitalizations in children with particular focus on neonates and young infants (≤42 days old) not eligible for vaccination. Ten years of Austrian surveillance data were compared, including 10 960 laboratory-confirmed RV cases before (prevaccination period [PreVP]) and after (postvaccination period [PostVP]) introduction of UMV.
RESULTS: A postvaccination decrease in hospitalized community-acquired RV infections by 89.3% was seen in all age groups, including unvaccinated neonates and young infants. Of the latter, 27.6% had a nosocomial RV infection in PreVP, and 19.3% in PostVP. Overall, the proportion of nosocomial RV infections increased from 5.5% in PreVP to 13.0% in PostVP. Breakthrough infections, usually after incomplete RV vaccination, could be identified in 6.2% of patients.
CONCLUSIONS: Unvaccinated neonates and infants ≤42 days old may indirectly benefit from UMV by reduction of RV infections. Breakthrough infections underline the importance of early and complete protection by the vaccine. In older patients, heightened awareness of nosocomial RV infections is warranted. Identification of RV reservoirs is also needed.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  infants; neonates; rotavirus; vaccination

Mesh:

Substances:

Year:  2016        PMID: 27190178     DOI: 10.1093/infdis/jiw186

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

Review 1.  Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality From Diarrhea.

Authors:  Eleanor Burnett; Christine L Jonesteller; Jacqueline E Tate; Catherine Yen; Umesh D Parashar
Journal:  J Infect Dis       Date:  2017-06-01       Impact factor: 5.226

Review 2.  A Case of Henoch-Schonlein Purpura Associated with Rotavirus Infection in an Elderly Asian Male and Review of the Literature.

Authors:  Chen Tang; Daphne Scaramangas-Plumley; Cynthia C Nast; Zab Mosenifar; Marc A Edelstein; Michael Weisman
Journal:  Am J Case Rep       Date:  2017-02-08

3.  Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting.

Authors:  P Bruijning-Verhagen; J A P van Dongen; J D M Verberk; R Pijnacker; R D van Gaalen; D Klinkenberg; H E de Melker; M-J J Mangen
Journal:  BMC Med       Date:  2018-09-10       Impact factor: 8.775

4.  Faecal shedding of rotavirus vaccine in Chinese children after vaccination with Lanzhou lamb rotavirus vaccine.

Authors:  Jin-Song Li; Bing Cao; Han-Chun Gao; Dan-di Li; Lin Lin; Li-Li Li; Na Liu; Zhao-Jun Duan
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

5.  Measuring indirect effects of rotavirus vaccine in low income countries.

Authors:  Aisleen Bennett; Naor Bar-Zeev; Nigel A Cunliffe
Journal:  Vaccine       Date:  2016-07-18       Impact factor: 3.641

6.  Report of the 5th European expert meeting on rotavirus vaccination (EEROVAC).

Authors:  Marieke L A de Hoog; Timo Vesikari; Carlo Giaquinto; Hans-Iko Huppertz; Federico Martinon-Torres; Patricia Bruijning-Verhagen
Journal:  Hum Vaccin Immunother       Date:  2018-01-18       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.